CENPA regulates tumor stemness in lung adenocarcinoma

Aging (Albany NY). 2022 Jul 11;14(13):5537-5553. doi: 10.18632/aging.204167. Epub 2022 Jul 11.

Abstract

Lung adenocarcinoma is a malignant and fatal respiratory disease. However, due to its complex pathogenesis and poorly effective therapeutic options, accurate early diagnosis and prognosis remain elusive. Now, there is increasing evidence that tumor stem cells are involved in tumorigenesis, metastasis, relapse, resistance to chemotherapy and radiotherapy and are one of the reasons why tumors cannot be cured. The mRNA expression based-stemness index (mRNAsi) is a parameter obtained by Malta and his colleagues applying innovative one-class logistic regression machine learning algorithm (OCLR) on mRNA expression in normal stem cells and their progeny. It is a valid evaluation parameter and is currently employed to evaluate the degree of differentiation of a certain tumor. In this study, we first used WGCNA and the software Cytoscape to obtain key modules and hub genes. We then applied LASSO regression analysis to calculate the genes in the key module to obtain a six-gene risk model. Moreover, the accuracy of this model was validated. Finally, we took the intersection of hub genes and risk genes and validated CENPA as both a tumor stemness regulator and a tumor prognostic factor in lung cancer.

Keywords: CENPA; cancer stem cell; lung adenocarcinoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung* / genetics
  • Biomarkers, Tumor / genetics
  • Cell Cycle Proteins / metabolism
  • Histones
  • Humans
  • Lung Neoplasms* / pathology
  • Neoplasm Recurrence, Local
  • Prognosis
  • RNA, Messenger / metabolism

Substances

  • Biomarkers, Tumor
  • Cell Cycle Proteins
  • Histones
  • RNA, Messenger